Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
view full news & meetings section

Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis


In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.

https://www.fapvoice.com/wp-content/uploads/2016/04/17.jpg

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close